Frontiers in Cellular and Infection Microbiology,
Год журнала:
2020,
Номер
10
Опубликована: Авг. 13, 2020
The
HIV
reservoir
remains
to
be
a
difficult
barrier
overcome
in
order
achieve
therapeutic
cure
for
HIV.
Several
strategies
have
been
developed
purge
the
reservoir,
including
"kick
and
kill"
approach,
which
is
based
on
notion
that
reactivating
latent
will
allow
subsequent
elimination
by
host
anti-HIV
immune
cells.
However,
clinical
trials
testing
certain
classes
of
latency
agents
(LRAs)
so
far
revealed
minimal
impact
reducing
viral
reservoir.
A
robust
response
reactivated
expressing
cells
critical
this
strategy
work.
current
focus
enhance
immunity
through
use
chimeric
antigen
receptors
(CARs).
Currently,
HIV-specific
CARs
are
being
applied
peripheral
T
cells,
NK
stem
boost
recognition
killing
infected
In
review,
we
summarize
developments
engineering
directed
CAR-expressing
facilitate
elimination.
We
also
LRAs
"kick"
how
new
generation
combinations
with
specific
CAR
cell
therapies
could
provide
an
optimal
target
clearance
from
body.
Signal Transduction and Targeted Therapy,
Год журнала:
2021,
Номер
6(1)
Опубликована: Май 14, 2021
Abstract
Rapid
development
of
vaccines
and
therapeutics
is
necessary
to
tackle
the
emergence
new
pathogens
infectious
diseases.
To
speed
up
drug
discovery
process,
conventional
pipeline
can
be
retooled
by
introducing
advanced
in
vitro
models
as
alternatives
disease
employing
technology
for
production
medicine
cell/drug
delivery
systems.
In
this
regard,
layer-by-layer
construction
with
a
3D
bioprinting
system
or
other
technologies
provides
beneficial
method
developing
highly
biomimetic
reliable
research.
addition,
high
flexibility
versatility
offer
advantages
effective
vaccines,
therapeutics,
relevant
Herein,
we
discuss
potential
control
We
also
suggest
that
research
could
significant
platform
rapid
automated
tissue/organ
medicines
near
future.
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2022,
Номер
10
Опубликована: Июнь 22, 2022
Adaptive
immunity,
orchestrated
by
B-cells
and
T-cells,
plays
a
crucial
role
in
protecting
the
body
from
pathogenic
invaders
can
be
used
as
tools
to
enhance
body’s
defense
mechanisms
against
cancer
genetically
engineering
these
immune
cells.
Several
strategies
have
been
identified
for
treatment
evaluated
their
efficacy
other
diseases
such
autoimmune
infectious
diseases.
One
of
most
advanced
technologies
is
chimeric
antigen
receptor
(CAR)
T-cell
therapy,
pioneering
therapy
oncology
field.
Successful
clinical
trials
resulted
approval
six
CAR-T
cell
products
Food
Drug
Administration
hematological
malignancies.
However,
there
various
obstacles
that
limit
use
CAR
first
line
mechanism
cancer.
Various
innovative
therapeutic
designs
preclinical
trial
settings
demonstrated
much
potential
development.
Such
testing
suitability
CARs
solid
tumors
HIV
are
showing
promising
results.
In
addition,
new
solutions
proposed
overcome
limitations
this
therapy.
This
review
provides
an
overview
current
knowledge
regarding
novel
technology,
including
structure,
different
applications,
limitations,
solutions.
Viruses,
Год журнала:
2024,
Номер
16(2), С. 219 - 219
Опубликована: Янв. 31, 2024
Chronic
Human
Immunodeficiency
Virus
(HIV)
infection
remains
a
significant
challenge
to
global
public
health.
Despite
advances
in
antiretroviral
therapy
(ART),
which
has
transformed
HIV
from
fatal
disease
into
manageable
chronic
condition,
definitive
cure
elusive.
One
of
the
key
features
is
immune
activation
and
inflammation,
are
strongly
associated
with,
predictive
of,
progression,
even
patients
successfully
treated
with
suppressive
ART.
inflammation
characterized
by
persistent
cell
metabolic
dysregulation,
cellular
exhaustion
dysfunction.
This
review
aims
summarize
current
knowledge
interplay
between
metabolism,
T
dysfunction
infection,
also
discusses
use
humanized
mice
models
study
pathogenesis
develop
novel
therapeutic
strategies.
Frontiers in Microbiology,
Год журнала:
2018,
Номер
9
Опубликована: Дек. 21, 2018
The
advances
in
cancer
biology
and
pathogenesis
during
the
past
two
decades,
have
resulted
immunotherapeutic
strategies
that
revolutionized
treatment
of
malignancies,
from
relatively
non-selective
toxic
agents
to
specific,
mechanism-based
therapies.
Despite
extensive
global
efforts,
infectious
diseases
remain
a
leading
cause
morbidity
mortality
worldwide,
necessitating
novel,
innovative
therapeutics
address
current
challenges
increasing
antimicrobial
resistance.
Similar
pathogenesis,
pathogens
successfully
fashion
hospitable
environment
within
host
modulate
metabolic
functions
support
their
nutritional
requirements,
while
suppressing
defenses
by
altering
regulatory
mechanisms.
These
parallels,
made
targeted
therapy
cancer,
may
inform
rational
development
therapeutic
interventions
for
diseases.
Although
"immunotherapy"
is
habitually
associated
with
this
review
accentuates
evolving
role
key
immune
are
approved,
as
well
those
development,
various
cancers
general
features
adoptive
therapies,
enhance
T
cell
effector
function,
ligand-based
neutralize
or
eliminate
diseased
cells,
discussed
context
specific
that,
date,
lack
appropriate
remedial
treatment;
HIV,
TB
drug-resistant
bacterial
fungal
infections.
remarkable
diversity
versatility
distinguishes
immunotherapy
emphasized,
consequently
establishing
approach
armory
curative
therapeutics,
applicable
across
disease
spectrum.
